Trial Profile
A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Bayer
- 18 Sep 2005 New trial record.
- 18 Sep 2005 New trial record.
- 18 Sep 2005 New trial record.